Rita Rubin's JAMA publication on FDA (VRBPAC) nightmarish seeking of vaccine for XBB.1.5 sub-variant (monovalent) tells us how reckless, inept FDA is! XBB.1.5 will be gone! (EG 5, XBB.2.3, XBB 1.16)
by Paul Alexander
Original antigenic sin (immune priming), ADEI/ADED; the concern is that mismatch between dominant sub-variant & vaccine-induced antibodies will drive selective pressure for more infectious subvariants
SOURCE:
Current bivalent COVID-19 vaccines take aim at the ancestral SARS-CoV-2 strain, first identified in December 2019 and targeted by the original monovalent vaccines, and the BA.4 and BA.5 Omicron subvariants, whose spike proteins are identical.
Even before the bivalent vaccines became available last September, though, the ancestral SARS-CoV-2 strain had disappeared, edged out by a Greek alphabet of variants leading up to Omicron and its offspring.’
More updated forecasting shows us that XBB.1.5 will no longer be the dominant variant by the time the new monovalent XBB.1.15 vaccine comes on tap (see my substack above)…
McCullough’s recent published forecast below is dated by one period (showing XBB.1.5) dominating at 27% but my above forecast shows EG5, XBB.1.16, XBB 2.3 as surging as XBB.1.5 fades (projected)):
See my prior substack:
Excellent stack by McCullough worth the read:
